ZJYL
Jin Medical International Ltd. (ZJYL) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Liquidity is adequate with a current ratio of 1.95 and quick ratio of 1.64, leaving ZJYL better positioned than more strained peers on near-term obligations.
Debt-to-equity of 0.68 suggests balance-sheet leverage is not extreme, which compares more favorably than highly geared peers despite limited profitability.
ROIC of 0.76% is positive, indicating capital is still deployed above zero returns, although it remains well below stronger peer benchmarks.
The very high cash conversion cycle of 243 days implies working-capital intensity, but it also reflects a business model that can support scale if execution improves.
Weaknesses
Net debt to EBITDA of 16.0x signals heavy leverage versus peers, constraining financial flexibility and making earnings volatility more damaging.
ROIC of 0.76% is structurally weak, showing capital is generating minimal returns relative to better-performing peers in the same market.
A cash conversion cycle of 243 days indicates slow cash recovery, which ties up capital longer than peers and depresses operating efficiency.
The absence of disclosed margin metrics limits transparency, but the available leverage and return data still point to a weaker competitive financial profile.
Opportunities
If ZJYL shortens its 243-day cash conversion cycle, it could release working capital faster than peers and improve liquidity without relying on external funding.
With current and quick ratios above 1.5, the company has room to absorb operational improvements that could translate into stronger peer-relative resilience.
Low ROIC leaves substantial headroom for operational upgrades, so even modest efficiency gains could materially improve positioning versus weaker peers.
Moderate debt-to-equity suggests refinancing or deleveraging actions could improve capital structure faster than for more overlevered competitors.
Threats
High net debt to EBITDA increases refinancing and covenant risk, making ZJYL more vulnerable than peers if credit conditions tighten.
Persistently low ROIC raises the risk that capital intensity will continue to destroy relative value, especially versus peers with stronger returns.
The long cash conversion cycle exposes the company to working-capital shocks, which can pressure liquidity more than in faster-converting peer models.
Because profitability metrics are not disclosed, peers with clearer margin strength may be viewed as structurally superior, limiting ZJYL's competitive standing.
Overall Score
ZJYL's structural positioning is weakened by very high leverage, low returns on capital, and slow cash conversion, while liquidity provides only partial offset versus peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Jin Medical International Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
